跳至主要内容
临床试验/NCT07012863
NCT07012863尚未招募4 期

Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting - - a Randomized Controlled Study

Vastra Gotaland Region0 个研究点目标入组 650 人开始时间: 2026年1月1日最近更新:
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
650
主要终点
Mortality

研究概览

简要总结

The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock.

Researchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.

详细描述

Major haemorrhage remains one of the leading causes of preventable early death after injury, and the window for effective intervention often closes in the pre-hospital phase. Contemporary European guidelines therefore advocate damage-control resuscitation: permissive hypotension, minimal crystalloid use and early infusion of blood components to avoid dilutional coagulopathy, acidosis and hypothermia. Several reports support that early resuscitation with blood products may save lives.

Freeze- or spray dried plasma containing coagulation factors having up to two years storage time and the possibility of storing ambient temperature, may be an alternative to crystalloids. The results regarding the beneficial results of treatment with plasma are ambiguous. In a previous randomized study using fresh plasma versus crystalloids, 9,8% reduced mortality was shown with resuscitation with plasma. Lower INR and lactate were also seen among the patients treated with plasma. In some studies no effect on mortality could be shown, but in other studies it is suggested that plasma may be beneficial in long transport time.

Acute traumatic coagulopathy can be seen in at least 25 % of severely injured patients who are admitted to a trauma centre. Dilution is often considered as a likely cause although the exact mechanisms and level of aggravation is unknown.

Most studies of prehospital bleeding refer to trauma, but also other causes of bleeding can be severe and even fatal, especially in countries with long distances, e.g. obstetric bleeding, gastrointestinal bleeding and vascular catastrophes.

Hypothesis. The hypothesis of this study is that prehospital treatment with dry plasma to bleeding patients improves the outcome compared to patients receiving standard treatment in terms of lower mortality, lower degree of coagulopathy and less need for blood products when in hospital.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.

排除标准

  • Patients < 18 years of age.
  • Patients who lack clinical signs of major bleeding.

研究组 & 干预措施

Dry plasma

Active Comparator

Patients randomized to this arm will get dry plasma as treatment for the bleeding.

干预措施: Dry plasma (Biological)

结局指标

主要结局

Mortality

时间窗: Within 24 hours after hospital admission.

Overall mortality at 24 hours after hospital admission. Will include patients dead at scene or during transportation.

次要结局

  • Mortality for patients with bleeding > 500 mL (milliliter)(Within 24 hours after hospital admission)
  • Shock Index(baseline, pre-intervention at scene)
  • Coagulopathy overall(Measured at hospital admission)

研究者

发起方
Vastra Gotaland Region
申办方类型
Other Gov
责任方
Sponsor

相似试验